GERON CORP OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment, before Tax
GERON CORP (GERN) reported OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment, before Tax of $88.00 thousand for the 12-month period ending 2024-12-31, per its 10-K filed 2026-03-02.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax · last filed 2026-03-02
- GERON CORP oci, debt securities, available-for-sale, gain (loss), after adjustment, before tax for fiscal 2024 was $88.00K.
- GERON CORP oci, debt securities, available-for-sale, gain (loss), after adjustment, before tax for fiscal 2023 was -$431.00K.
- GERON CORP oci, debt securities, available-for-sale, gain (loss), after adjustment, before tax for fiscal 2022 was -$68.00K.
- GERON CORP oci, debt securities, available-for-sale, gain (loss), after adjustment, before tax for fiscal 2021 was -$251.00K.
| Period end | OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment, before Tax 12 month |
|---|---|
| 2024-12-31 | $88.00K 10-K · filed 2026-03-02 |
| 2023-12-31 | -$431.00K 10-K · filed 2026-03-02 |
| 2022-12-31 | -$68.00K 10-K · filed 2025-02-27 |
| 2021-12-31 | -$251.00K 10-K · filed 2024-02-28 |
| 2020-12-31 | -$54.00K 10-K · filed 2023-03-16 |
| 2019-12-31 | $315.00K 10-K · filed 2022-03-10 |
| 2018-12-31 | $24.00K 10-K · filed 2021-03-11 |
| 2017-12-31 | -$154.00K 10-K · filed 2020-03-12 |
| 2016-12-31 | $160.00K 10-K · filed 2019-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B |